文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

肺动脉导管置入对非缺血性心源性休克患者的影响:全国性分析

EFFECT OF PULMONARY ARTERY CATHETERIZATION IN PATIENTS WITH NONISCHEMIC CARDIOGENIC SHOCK: A NATIONWIDE ANALYSIS.
PubMed 文献 · Shock · 2024-04-09
一句话结论全国性回顾性队列显示,非缺血性心源性休克患者使用肺动脉导管与住院死亡率降低相关(24.8% vs 35.3%)。

本研究为回顾性队列研究,利用美国全国住院患者样本数据库,纳入2017至2019年成人非缺血性心源性休克住院患者,比较肺动脉导管(PAC)组与非PAC组的住院结局,采用逆概率治疗加权校正混杂。共纳入303,970例患者,17.5%接受PAC,中位年龄67岁(四分位距57-77),61%为男性。加权后PAC组住院死亡率显著低于非PAC组(24.8% vs 35.3%,P<0.001),肾脏替代治疗(10.7% vs 12.4%,P=0.002)、住院期间心脏骤停(7.1% vs 9.6%,P<0.001)和机械通气(44.6% vs 50.4%,P<0.001)均显著减少。但PAC组主动脉内球囊反搏(15.4% vs 3.4%,P<0.001)、经皮心室辅助装置(12.6% vs 2.6%,P<0.001)、体外膜肺氧合(3.9% vs 2.5%,P<0.001)和心脏移植(2.1% vs 0.4%,P<0.001)使用率更高。结论认为在真实世界中,PAC血流动力学监测与生存获益及不良事件减少相关。

要点

  • 非缺血性心源性休克患者中,PAC组住院死亡率24.8% vs 非PAC组35.3%,P<0.001。
  • PAC组肾脏替代治疗10.7% vs 12.4%(P=0.002),住院期间心脏骤停7.1% vs 9.6%(P<0.001),机械通气44.6% vs 50.4%(P<0.001),均显著低于非PAC组。
  • PAC组主动脉内球囊反搏使用率15.4% vs 3.4%(P<0.001),经皮心室辅助装置12.6% vs 2.6%(P<0.001),体外膜肺氧合3.9% vs 2.5%(P<0.001),心脏移植2.1% vs 0.4%(P<0.001),均显著高于非PAC组。
  • 研究纳入303,970例非缺血性心源性休克患者,17.5%接受PAC,中位年龄67岁(四分位距57-77),61%为男性。

适用人群与场景

  • 成人非缺血性心源性休克住院患者,数据来自2017至2019年全国住院患者样本数据库。

研究设计与关键结果

  • 回顾性队列研究,纳入303,970例非缺血性心源性休克成人患者,17.5%接受PAC,中位年龄67岁(四分位距57-77),61%为男性;采用逆概率治疗加权比较住院结局。
  • 加权后PAC组住院死亡率24.8% vs 非PAC组35.3%,P<0.001。
  • PAC组肾脏替代治疗10.7% vs 12.4%,P=0.002;住院期间心脏骤停7.1% vs 9.6%,P<0.001;机械通气44.6% vs 50.4%,P<0.001。
  • PAC组主动脉内球囊反搏15.4% vs 3.4%,P<0.001;经皮心室辅助装置12.6% vs 2.6%,P<0.001;体外膜肺氧合3.9% vs 2.5%,P<0.001;心脏移植2.1% vs 0.4%,P<0.001。

证据类型、等级与局限

  • 证据类型:回顾性队列研究;局限:原文未报告局限性。

对床旁实践的改变

  • 在真实世界中,非缺血性心源性休克患者使用PAC进行有创血流动力学监测与生存获益及不良事件减少相关(住院死亡率24.8% vs 35.3%,P<0.001)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Pulmonary artery catheterization (PAC) has been widely used in critically ill patients, yielding mixed results. Prior studies on cardiogenic shock (CS) predominantly included patients with acute myocardial infarction. This study aims to examine the effect of PAC use in patients with nonischemic CS. Methods: This retrospective cohort study employed data from the National Inpatient Sample database, including weighted hospitalizations of adult patients with nonischemic CS during 2017 to 2019. In-hospital outcomes were compared between groups using inverse probability of treatment weighting. Results: A total of 303,970 patients with nonischemic CS were included, of whom 17.5% received a PAC during their hospitalization. The median age was 67 years (interquartile range: 57-77) and 61% were male. After inverse probability of treatment weighting, patients in the PAC group had significantly lower in-hospital mortality (24.8% vs. 35.3%, P < 0.001), renal replacement therapy (10.7% vs. 12.4%, P = 0.002), in-hospital cardiac arrest (7.1% vs. 9.6%, P < 0.001), and mechanical ventilation (44.6% vs. 50.4%, P < 0.001) compared to non-PAC group. In contrast, the PAC group had higher use of intra-aortic balloon pump (15.4% vs. 3.4%, P < 0.001), percutaneous ventricular assist devices (12.6% vs. 2.6%, P < 0.001), extracorporeal membrane oxygenation (3.9% vs. 2.5%, P < 0.001), and heart transplantation (2.1% vs. 0.4%, P < 0.001). Conclusion: In the real-world setting, invasive hemodynamic monitoring with PAC in patients with nonischemic CS is associated with survival benefits and a reduction in adverse events, including reduced need for renal replacement therapy, mechanical ventilation and risk of in-hospital cardiac arrest.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Diaz-Arocutipa C, Moreno G, Gil DG, et al. EFFECT OF PULMONARY ARTERY CATHETERIZATION IN PATIENTS WITH NONISCHEMIC CARDIOGENIC SHOCK: A NATIONWIDE ANALYSIS. Shock. 2024. PMID: 38661168. doi:10.1097/SHK.0000000000002371

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。